Gapping down
In reaction to earnings/guidance:
ASUR -16.3%, NVT -6.1%, DBRG -6%, TDS -5.7%, BJRI -5.6%, AMCR -4.5% (also to sell its 50% interest in Bericap North America for $122 mln; also raises dividend), GTLS -3.7%, FOXF -3.4%, ESNT -3.3%, RMAX -3%, CUBI -2.7%, KWR -2.7%, EMN -2.5%, EGO -2.2%, IR -2%, AAPL -1.8% (also files debt securities shelf offering for an undisclosed amount), SM -1.6%, CTRA -1.5%, RGA -1.5%, ZYME -1.5%, AMED -1.4%, CAR -1.3%, TNC -1.2% (also increases dividend), LNT -1.1% (also expects to increase dividend in FY25), VIAV -1.1%
Other news:
EPIX -70% (Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer)
LXRX -34.4% (FDA panel votes 11-3 against benefits for LXRX's Sotagliflozin)
ARBE -19.2% (stock offering)
ASPI -9.3% (stock offering)
MYO -3% (MyoPro to be provided to patients covered by private insurance)
BWMN -1.6% (to acquire Exeltech)
PTON -1.2% (MEC and PTON resolve litigation)